Skip to main content
Verghese Mathew, MD, Cardiology, Chicago, IL, Swedish Hospital

VergheseMathewMDFACC, FSCAI

Cardiology • Chicago, IL

Interventional Cardiology

Director Interventional Cardiology Swedish Hospital NorthShore University HealthSystem Chicago, Illinois

Join to view full profile

Dr. Mathew is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mathew's full profile

Already have an account?

Summary

  • Dr. Mathew is Director, Interventional Cardiology at Swedish Hospital NorthShore University HealthSystem. He is also Director of WNICER, a global think tank and clinical trials collaborative which includes over 400 investigators around the world that have worked together on various trials, funded through federal and other sources. Until December, 2019 he was the Director, Division of Cardiology at Loyola University Medical Center, and held the rank of Professor of Medicine at Loyola University Chicago Stritch School of Medicine, and the William B. Knapp, MD Chair in Cardiology.

    Dr. Mathew has been a high volume academic interventional cardiologist for more than 2 decades. He was a consultant cardiologist at Mayo Clinic from 1997-2016, holding a number of leadership positions in the cardiac and vascular arenas, with joint appointments in the departments of medicine, cardiology, and radiology; he was recruited to Loyola University Medical Center in 2016 to lead the division of cardiology.

    Dr. Mathew has done extensive work in the field of interventional cardiology including complex CAD, peripheral arterial interventions, and TAVR- with both basic and translational research programs. He has been an investigator in many trials that have evaluated and led to the approval of currently utilized technologies, such as coronary stents/drug eluting stents and transcatheter aortic valve replacement (TAVR); as well as phase II-IV pharmacologic studies focused on antiplatelet and anticoagulant drugs in the context of coronary interventions. He has published extensively in the field of interventional cardiology. Dr. Mathew has a keen interest in integrated models of care, focusing on the appropriate application of advanced cardiovascular therapies to complex patient subsets. He continues to be an invited speaker at many national and international cardiovascular scientific conferences.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Interventional Cardiology, 1996 - 1997
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 1993 - 1996
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1990 - 1993
  • Loyola University Chicago Stritch School of Medicine
    Loyola University Chicago Stritch School of MedicineClass of 1990
  • Northwestern University
    Northwestern UniversityBA, Chemistry, 1983 - 1986

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1992 - 2026
  • IL State Medical License
    IL State Medical License 2016 - 2026
  • WI State Medical License
    WI State Medical License 2007 - 2025
  • AZ State Medical License
    AZ State Medical License 2012 - 2018
  • MN State Medical License
    MN State Medical License 1991 - 2017
  • American Board of Internal Medicine Cardiovascular Disease
  • American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

  • Fellow Society for Cardiovascular Angiography and Interventions
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention  
    Naveen L Pereira, Verghese Mathew, Charles Cagin, Amir Lerman, Charanjit Rihal, JAMA

Lectures

  • Basics of Coronary Angiography: Setup, Views, and Equipment 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/25/2019

Authored Content

  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionAugust 2020
  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionAugust 2020
  • Targeting Inflammation in the Prevention and Treatment of Type 2 Diabetes Insights from CANTOSMay 2018

Press Mentions

  • Grateful Heart Patient Gives $1.5 Million Gift to Loyola Medicine Cardiology Division
    Grateful Heart Patient Gives $1.5 Million Gift to Loyola Medicine Cardiology DivisionJune 3rd, 2019
  • Mono-Antiplatelet Therapy After Aortic Heart Valve Replacements May Work as Well as Two Drugs
    Mono-Antiplatelet Therapy After Aortic Heart Valve Replacements May Work as Well as Two DrugsAugust 14th, 2018
  • Cardiovascular Update C L I N I C a L Ca R D I O L O G Y a N D C a R D I O Va S C U L a R S U R G E R Y N E W S
    Cardiovascular Update C L I N I C a L Ca R D I O L O G Y a N D C a R D I O Va S C U L a R S U R G E R Y N E W SJuly 6th, 2017

Professional Memberships

Hospital Affiliations

Dr. Verghese Mathew, Dr. Verghese Mathew, MD, Dr. V Mathew